Analysts rate Regeneron Pharmaceuticals Inc. with a Buy rating and a 12-month average target price of $667.95 per share.
Jefferies Financial LLP Downgraded Regeneron Pharmaceuticals Inc. to a Sell rating and maintains the target price at $536 on the company’s stock.
Based on the Regeneron Pharmaceuticals Inc stock forecasts from 14 analysts, the average analyst target price for Regeneron Pharmaceuticals Inc is USD 667.95 over the next 12 months. Regeneron Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Regeneron Pharmaceuticals Inc is Bullish , which is based on 9 positive signals and 3 negative signals. At the last closing, Regeneron Pharmaceuticals Inc’s stock price was USD 580.95. Regeneron Pharmaceuticals Inc’s stock price has changed by +9.14% over the past week, -76.20% over the past month and +8.00% over the last year.
Regeneron Pharmaceuticals, Inc. develops, manufactures, and sells pharmaceuticals to treat a variety of diseases around the world. The business was founded in 1988 and is based in Tarrytown, New York.
What we like:
High market capitalization
This is one of the largest entities in its sector and is among the top quartiles. Such companies tend to be more stable.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What we don’t like:
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced compared to book value
The stock is trading high compared to its peer’s median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering buying.
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.